FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

Kalshi Health › FDA & drugs Closes Dec 31 · $17 today · $1.2K traded · $753 at stake · prices read 2 h ago

The odds

74%chance▼ 1

How the odds have moved

Yes: 72% on Oct 19, 74% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome	Chance	Day	Bid	Ask	Pays	Contracts
Yes	74%	▼ 1	70¢	78¢	$1.28	1.7K

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Zydus Therapeutics, Saroglitazar

Search ›

Zydus Therapeutics reveals promising Phase 2b trial results for saroglitazar in MASH treatmentTaxGuru · 3 days agoZydus Therapeutics reports positive Phase 2b EVIDENCES X trial results for saroglitazar in MASH patients, showing improved liver health and tolerability. Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced…
Zydus Therapeutics Presents Phase 2b Data at AASLD 2026 Showing Greater Resolution of Steatohepatitis Without Worsening of Fibrosis With Investigational Saroglitazar Compared to Placebo in Adults With MASH and Fibrosis@PRNewswire · 3 days ago/PRNewswire/ -- Zydus Therapeutics Inc. ("Zydus Therapeutics"), a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation-led healthcare... - Resolution of steatohepatitis without worsening of fibrosis was achieved by…
Zydus Lifesciences unveils promising Phase 2b trial results for saroglitazar in MASH treatmentBusiness Upturn · 4 days agoZydus Lifesciences announced promising Phase 2b trial results for saroglitazar in treating MASH and fibrosis, showing significant clinical improvements. Zydus Lifesciences unveils promising Phase 2b trial results for saroglitazar in MASH…
Saroglitazar Resolves MASH Without Fibrosis Worsening: EVIDENCES X@MDMagazine · 3 days agoIn the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks. Chalasani and Arun Sanyal, MD, of Virginia Commonwealth University, served as…
Saroglitazar Cuts Blood Sugar More Than Dapagliflozin in Fatty Liver StudyBIOENGINEER.ORG · 4 days agoA 25-week Indian cohort study found both saroglitazar and dapagliflozin improved liver fat and metabolic markers in MASLD patients, with saroglitazar showing a significantly greater HbA1c reduction. Subject of Research: Comparative…
FDA grants tentative approval to low-cost HIV shotsemafor.com · 5 days agoThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulatorsâ approval of a cheaper HIV shot has lifted hopes in some of the worldâs poorest countries…
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara@PRNewswire · 42 h agoMELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New…
Novartis Gene Therapy Under FDA Scrutinyiotwreport.com · 2 days agoReuters The US Food and Drug Administration said on Friday it was investigating a risk... The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated…
Inferior Vena Cava Filter Use Fell After FDA Warning but Remains HighTCTMD.com · 43 h agoUse of inferior vena cava (IVC) filters declined in the United States following a 2010 safety communication from the US Food and Drug Administration (FDA), although the rate of implantation remains much higher than that seen in Europe…
Maharashtra FDA Declares Wellness Capsules Spurious After Detecting Undisclosed Erectile Dysfunction DrugFree Press Journal · 2 days agoMumbai, November 7, 2026: A capsule marketed as Urja Urbpro has been declared spurious after laboratory tests detected tadalafil, a prescription drug commonly used to treat erectile dysfunction, in the product without it being declared as…
Deaths prompt CPSC, FDA warning on infant sleep positionerscpsc.gov · 3 days agoMost of the infants suffocated after rolling from a side to stomach position. In addition to the reported deaths, CPSC has received dozens of reports of infants who were placed on their backs or sides in sleep positioners, only to be found…
FDA probes tumour risk tied to Novartis gene therapyTradingView · 3 days agoTradingView FDA probes tumour risk tied to Novartis gene therapy

Related markets

All fda & drugs ›

Health › FDA & drugs

When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)

98%before December

before December98%▲ 6
before 202798%▲ 5
before April 202798%

Health › FDA & drugs

Will the FDA approve retatrutide? (retatrutide (LY3437943))

Dec 9, 2027even chance by

Before Jan 1, 20272%
Before Jul 1, 202712%▼ 9
Before Jan 1, 202856%

2 more

Before Jul 1, 202885%
Before Jan 1, 202990%

Health › FDA & drugs

Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

16%chance▼ 1

Health › FDA & drugs

When will the FDA reclassify BPC-157 to Category 1?

10%Before 2027

Before 202710%▲ 1

Health › FDA & drugs

When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)

90%Before 2028

Before 202890%▼ 1
Before October 202788%▼ 1
Before July 202787%

2 more

Before Mar 1, 202765%▼ 1
Before Jan 1, 202719%▲ 2

Health › FDA & drugs

When will Beam Therapeutics submit a BLA for Risto-cel?

93%before April 2027

before April 202793%▲ 15
before 202756%▼ 1
before December14%

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 2 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

About this market

VenueKalshi

Settles onAppliedXL

Trading closesDec 31, 2026 11:59 PM ET

Traded$1.2K (1,675 contracts)

Today$17

This week$171

At stake$753

In the news100 headlines today, 809 this week

Followed here sinceOct 19, 2026

The rules

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

The full rules are on the market's page at Kalshi.

Reading the odds

A prediction market trades contracts that pay $1 if something happens. Its price is the market's chance: a contract at 62¢ means traders give it 62%. Each number here is the midpoint between the best bid and offer, or the last trade when they are more than ten cents apart.

For a question with many answers (who wins, which range a number lands in), the chances are scaled to add up to 100%. A price ladder ("above 4.25%, above 4.50% ...") gives a whole distribution: its median is where traders see an even chance either way.

Kalshi is a U.S. exchange regulated by the CFTC; its money is counted in contracts, shown here as dollars at their price. Polymarket counts dollars. ForecastEx is Interactive Brokers' exchange, regulated by the CFTC; its contracts too are shown as dollars at their price. Crypto.com lists its markets on Crypto.com | Derivatives North America, a U.S. exchange regulated by the CFTC; it reports the dollars traded. Where more than one asks the same question, each is shown, never averaged.

Prefer betting odds? Switch to American (+150) or decimal (2.50) odds at the top of the page.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions